• Guardant Health secured Carelon Healthcare Services coverage for its FDA-approved Shield blood test for colorectal cancer screening, effective Nov. 15.
• Policy expands commercial access to about 90 million covered lives, roughly 75% of eligible US adults age 45 and older.
• Coverage applies to average-risk members under Carelon’s medical benefit management, which serves Blue Cross Blue Shield plans across 26 states.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609010805BIZWIRE_USPR_____20260901_BW544822) on September 01, 2026, and is solely responsible for the information contained therein.